NCT07223242 Tailored Exercise Training Study Among Adults With HFpEF
| NCT ID | NCT07223242 |
| Status | Recruiting |
| Phase | Phase 2, Phase 3 |
| Sponsor | University of Texas Southwestern Medical Center |
| Condition | HFpEF - Heart Failure With Preserved Ejection Fraction |
| Study Type | INTERVENTIONAL |
| Enrollment | 120 participants |
| Start Date | 2025-02-18 |
| Primary Completion | 2026-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 120 participants in total. It began in 2025-02-18 with a primary completion date of 2026-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Heart failure with preserved ejection fraction (HFpEF) is associated with a high morbidity and mortality burden. There are limited pharmacological options available for the treatment of HFpEF. Exercise intolerance (EI) is the cardinal symptom of HFpEF, which manifests as dyspnea and fatigue. EI leads to functional deconditioning and reduced quality of life (QOL), both of which elevate risk of death and hospitalization in patients with HFpEF. Supervised exercised training is associated with improvements in exercise capacity and QOL in adults with HFpEF. However, supervised exercise has not been widely utilized for the treatment of HFpEF due to logistical and fiscal barriers. This study will investigate the effects of a remote exercise training intervention on exercise capacity and skeletal muscle composition in patients with HFpEF, or those at risk for it. In addition, it will compare four different lifestyle interventions for their effects on exercise capacity.
Eligibility Criteria
Inclusion Criteria: 1. Age\>= 18 yrs 2. LVEF (Left Ventricular Ejection Fraction) \>= 50% 3. History of HFpEF or at risk of HFpEF 1. HFpEF diagnosis based on:- -HF hospitalization within 12 months- * NT-proBNP \>360 pg/mL 2. Risk of HFpEF based on:- * \>2 risk factors (h/o diabetes, hypertension, obesity, physical inactivity by self-report) 4. SPPB \< 10 or VO2\<60th percentile 5. BMI \>=28 (for randomization in phase II) 6. Able to use cell phone and mobile application Exclusion Criteria: 1. Hospitalization 1 month prior to baseline visit 2. History of recurrent falls 3. eGFR (Estimated Glomerular Filtration Rate) \<20ml/min/1.73m 4. Active changes in HF therapies over 2 weeks prior to baseline visit 5. Inability participate in exercise training therapy 6. Inability to perform CPET (Cardiopulmonary Exercise Testing) testing 7. Severe left side valvular heart disease 8. End stage pulmonary disease, requiring continuous supplemental oxygen 9. Major surgery within 3 months of screening or major elective surgery during the duration of the study. 10. Unstable weight defined by \>5% change in body weight in last 30 days before first study visit. 11. Pregnancy
Frequently Asked Questions
Who can join the NCT07223242 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying HFpEF - Heart Failure With Preserved Ejection Fraction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07223242 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07223242 currently recruiting?
Yes, NCT07223242 is actively recruiting participants. Visit ClinicalTrials.gov or contact University of Texas Southwestern Medical Center to inquire about joining.
Where is the NCT07223242 trial being conducted?
This trial is being conducted at Dallas, United States.
Who is sponsoring the NCT07223242 clinical trial?
NCT07223242 is sponsored by University of Texas Southwestern Medical Center. The trial plans to enroll 120 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.